TrialNature communications2025

Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial.

Paolo Strati et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.